Beijing Sun-Novo Pharmaceutical Research Co Ltd
SSE:688621
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| CN |
|
Beijing Sun-Novo Pharmaceutical Research Co Ltd
SSE:688621
|
7.3B CNY |
Loading...
|
|
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
1.1T USD |
Loading...
|
|
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
195.3B USD |
Loading...
|
|
| US |
|
Danaher Corp
NYSE:DHR
|
147.9B USD |
Loading...
|
|
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
79.2T KRW |
Loading...
|
|
| CH |
|
Lonza Group AG
SIX:LONN
|
36.7B CHF |
Loading...
|
|
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
280.9B CNY |
Loading...
|
|
| US |
|
Agilent Technologies Inc
NYSE:A
|
34.3B USD |
Loading...
|
|
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
29.9B USD |
Loading...
|
|
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
27.8B USD |
Loading...
|
|
| CN |
|
WuXi Biologics (Cayman) Inc
HKEX:2269
|
164.2B HKD |
Loading...
|
Market Distribution
| Min | -2 148% |
| 30th Percentile | 14.3% |
| Median | 23% |
| 70th Percentile | 34.6% |
| Max | 775.2% |
Other Profitability Ratios
Beijing Sun-Novo Pharmaceutical Research Co Ltd
Glance View
Beijing Sun-Novo Pharmaceutical Research Co., Ltd. engages in the research and development of pharmaceutical products. The company is headquartered in Beijing, Beijing and currently employs 873 full-time employees. The company went IPO on 2021-06-21. The firm's main businesses include comprehensive research and development services in generic drug development, consistency evaluation and innovative drug development. Its services mainly include pharmaceutical research, clinical trials and biological analysis. Pharmaceutical research services include raw materials and preparation process research, quality standards and stability research, etc. Clinical trial services include phase I-IV clinical trial research, Bioequivalency (BE) test research. Biological analysis services include the use of mass spectrometry analysis platform, immunoassay platform, cell analysis platform, molecular biology analysis platform for method development, method validation, biological sample detection research, etc. The firm mainly conducts its businesses in the domestic market.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for Beijing Sun-Novo Pharmaceutical Research Co Ltd is 47.7%, which is below its 3-year median of 53.3%.
Over the last 3 years, Beijing Sun-Novo Pharmaceutical Research Co Ltd’s Gross Margin has decreased from 55.1% to 47.7%. During this period, it reached a low of 46.8% on Mar 31, 2025 and a high of 59.1% on Mar 31, 2024.
